HOME > BUSINESS
BUSINESS
- Otsuka HD’s Vice Chairman Otake Resigns for “Personal Reasons”
July 17, 2012
- Bioventure Industry Caught in Negative Spiral: DBJ Report
July 17, 2012
- Cumulative Sales of Japan’s 1st Emergency Contraceptive NorLevo Nears 50,000 Packs in 1 Year
July 16, 2012
- RIJ Plans World’s First Trial of iPS Cell Therapy in Men: President & CEO Kagimoto
July 16, 2012
- Shionogi Announces Positive Results of Second PIII Study for Dolutegravir
July 13, 2012
- Daiichi Sankyo to Receive METI’s Grant for Its Biopharmaceutical Production Facility Expansion
July 13, 2012
- Astellas to Develop Companion Diagnostic Agents in Collaboration with Other Companies: President Hatanaka
July 13, 2012
- Yoshindo to Develop Biopharmaceutical Business in 3 Steps: President Shimomura
July 13, 2012
- Taiho, Teikoku Form Alliance for Cancer Pain Reliever
July 12, 2012
- Teijin Pharma to Boost New Drug Ratio to More than 50%, Prepare “Post-Feburic” Products: President Arao
July 12, 2012
- Micro Marketing Method to Be Potentially Effective in Future: Ninomiya of Novartis Pharma
July 12, 2012
- Bayer HealthCare Initiates Multinational PIII Trial for Hemophilia A Treatment BAY94-9027
July 12, 2012
- Nippon Chemiphar Aiming to Boost Generic Drug Sales to 30 Billion Yen in FY2014: President Yamaguchi
July 12, 2012
- Shionogi Files Lawsuit against InterMune of US over Royalties Payment
July 12, 2012
- Astellas Transfers 2 APIs Including Psychotropic Agent to Maruishi
July 11, 2012
- Astellas Transfers 2 APIs Including Psychotropic Agent to Maruishi
July 11, 2012
- Halaven Fails to Meet Primary Endpoints vs Capecitabine in PIII Study: Eisai
July 11, 2012
- Suzuken to Offer Voluntary Early Retirement Program for Record 500 Employees
July 11, 2012
- BMKK Applies for Orencia SC Injection
July 11, 2012
- Takeda to Offer US Dollar Senior Notes for Repaying Debt for Nycomed Acquisition
July 11, 2012
ページ
Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…